Contribute Try STAT+ Today

In an unexpected development, AbbVie (ABBV) is waiving restrictions on licenses held by a nonprofit for its Kaletra HIV pill so that other companies can supply the medicine anywhere in the world. As part of the decision, the drug maker will no longer enforce patent rights relating to adults or children.

Notably, the move by AbbVie came after the Israeli government last week approved a license to purchase a generic copy of Kaletra after speculation rose that the pill could be used to combat the novel coronavirus, even though a paper published a few days earlier in the New England Journal of Medicine raised doubts about its effectiveness to do so.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.